sorbitol pathway

(redirected from Polyol pathway)
Also found in: Wikipedia.

sor·bi·tol path·way

a pathway responsible for d-fructose formation from sorbitol; increases in activity as the glucose concentration rises in diabetes.
Synonym(s): polyol pathway
References in periodicals archive ?
One of the mechanisms that can cause diabetic cataracts is the activation of polyol pathway enzymes and increasing their products, which cannot diffuse passively out of the lenses and cause osmotic stress leading to lens hydration and swelling.
Aldose reductase (AR) is the first and rate-limiting enzyme in polyol pathway, which catalyzes the reduction of glucose to sorbitol and then sorbitol can be converted to fructose by sorbitol dehydrogenase (SDH).
Aldose reductase inhibitors can block the polyol pathway and have been used to deliberate the development of diabetic cardiovascular autonomic neuropathy (DCAN).
4] Hyperglycemia may cause vessel damage through at least three apparently unrelated pathway: advanced glycation end product (AGE) formation, activation of protein kinase C (PKC) and sorbitol accumulation by way of polyol pathway.
The all important pericyte loss in DR is discussed in the next chapter, the polyol pathway, the role of the pericyte in maintaining functional and structural integrity is well written.
Some of the key pathways involved in diabetic nephropathy include the polyol pathway, activation of protein kinase C, generation of advanced glycation products, activation of cytokines and generation of reactive oxygen species.
Researchers have shown that both enzymes of the polyol pathway contributed to hyperglycemia-induced oxidative stress in the lens, and likely cause neuronal dysfunction as well.
14) Oxidative stress, AGE accumulation, and the polyol pathway are all implicated in diabetic neuropathy.
The enzymes aldose reductase and sorbitol dehydrogenase play key roles in the polyol pathway (Winegrad, 1987).
Aldose reductase and the role of the polyol pathway in diabetic nephropathy.
Aldose reductase (AR) catalyzes glucose to sorbitol, and then sorbitol dehydrogenase converts sorbitol to fructose in the polyol pathway of glucose metabolism.
Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.